Drawing for EZZAMBRIS

USPTO serial 87195503

EZZAMBRIS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
MACIOL II, EUGENE VALENTINE-JO
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with EZZAMBRIS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Bruce W. Longbottom

BRUCE W. LONGBOTTOM ELI LILLY AND COMPANYLILLY CORPORATE CENTERINDIANAPOLIS, IN 46285UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, pain, pancreatic diseases and disorders, Parkinson's disease, psychiatric disorders, sleep disorders, urological disorders; antidepressants; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseasesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Nov 20, 2017MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 20, 2017ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 18, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 21, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Feb 21, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 1, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jan 18, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 14, 2017DOCKASSIGNED TO EXAMINER—
Oct 13, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 10, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance